Silk Road Medical, Inc (NASDAQ:SILK) Q3 2022 Earnings Call Transcript

Adam Maeder: That’s really helpful, Erica. Thank you for that color. And if I could sneak in one more if you don’t mind just on Japan. Congratulations on Shonin approval. It sounds like next steps are reimbursement and the post-market approval study. Just wondering if you can give us any broader thoughts on timing there. Really the simple question is should we have any revenue dialed into our model in ’23 or is it more likely a 2024 contributor? Thank you so much.

Erica Rogers: Yeah. Sure, Adam. So first of all, yes, we are thrilled with the approval in Japan. And as you probably know, Japan is kind of a methodical progress toward commercial launch and it really starts at the approval. The things that we are thinking about and working on now are the reimbursement submission, the post-market study requirements and of course really understanding the best kind of go-to-market strategy in Japan. As we said before, Japan is a relatively small market compared to say for example the U.S. or China. But it is strategically important to us because we like the neurosurgery call point, which is the same clinician performing neurointerventional procedures as you probably know. And so the way to think about it is it’s not revenue in 2023 and perhaps longer, but we’ll wait to give you more clarity on that.

Adam Maeder: Okay. Understood. Thank you.

Operator: Thank you, Adam. At this time, I would like to turn it back to Erica Rogers for some closing remarks.

Erica Rogers: Well, thank you very much for joining us. We couldn’t be more pleased with our progress in the third quarter. Thank you again.

Operator: Thank you for your participation in today’s conference. This does conclude the program and you may now disconnect.